Advanced search
Publication Cover
Leukemia & Lymphoma Volume 33, 1999 - Issue 5-6
Submit an article Journal homepage
55
Views
20
CrossRef citations to date
0
Altmetric
Original Article

Intensive Chemotherapy with Hematopoietic Cell Transplantation after ESHAP Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma. Results of a Single-Centre Study of 65 Patients

Carole Soussain Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
Bertrand Souleau Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
Jean Gabarre Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
Hamadi Zouabi Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
Laurent Sutton Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
Catherine Boccaccio Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
Nicolas Albin Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
FrÉDÉRic Charlotte Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
HÉLÉNe Merle-béral Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
JosÉE Delort Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
,
Jacques-Louis Binet Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
&
VÉRonique Leblond Department of Hematology, Hôpital Pitié-Salpétrière, 47-83, Boulevard de l'Höpital - 75651, Paris, Cedex, 13, France
 show all
Pages 543-550 | Accepted 22 Aug 1998, Published online: 01 Jul 2009

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Alden A. Moccia, Felicitas Hitz, Paul Hoskins, Richard Klasa, Maryse M. Power, Kerry J. Savage, Tamara Shenkier, John D. Shepherd, Graham W. Slack, Kevin W. Song, Randy D. Gascoyne, Joseph M. Connors & Laurie H. Sehn. (2017) Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leukemia & Lymphoma 58:2, pages 324-332.
Read now
Rodica Ungur, Adrian Tempescul, Christian Berthou, Cristina Bagacean, Doinel Radeanu, Adriana Muresan & Mihnea Zdrenghea. (2015) ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases. OncoTargets and Therapy 8, pages 2771-2773.
Read now
Niels Murawski, Carsten Zwick & Michael Pfreundschuh. (2010) Unresolved issues in diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy 10:3, pages 387-402.
Read now
Heng-Xiang Wang, Hong-Min Yan, Jing Liu, Lian-Ning Duan, Zhi-Dong Wang, Ling Zhu, Mei Xue & Zi-Kuan Guo. (2009) Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. Leukemia & Lymphoma 50:9, pages 1488-1493.
Read now
T. Seshadri, J. Stakiw, M. Pintilie, A. Keating, M. Crump & J. Kuruvilla. (2008) Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy. Hematology 13:5, pages 261-266.
Read now
Johannes Atta, Kai U. Chow, Eckhart Weidmann, Paris S. Mitrou, Dieter Hoelzer & Hans Martin. (2007) Dexa-BEAM as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma. Leukemia & Lymphoma 48:2, pages 349-356.
Read now

Articles from other publishers (14)

R. Garcia-Sanz, A. Sureda, F. de la Cruz, M. Canales, A.P. Gonzalez, J.L. Pinana, A. Rodriguez, A. Gutierrez, E. Domingo-Domenech, B. Sanchez-Gonzalez, G. Rodriguez, J. Lopez, M. Moreno, M.J. Rodriguez-Salazar, S. Jimenez-Cabrera, M.D. Caballero & C. Martinez. (2019) Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Annals of Oncology 30:4, pages 612-620.
Crossref
Eisei Kondo. (2016) Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma. Journal of Clinical and Experimental Hematopathology 56:2, pages 100-108.
Crossref
Monica Sierra del Rio, Sylvain Choquet, Khé Hoang-Xuan, Sylvie Glaisner, Emmanuelle Fourme, Maud Janvier & Carole Soussain. (2011) Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. Journal of Neuro-Oncology 105:2, pages 409-414.
Crossref
Carsten Zwick, Niels Murawski & Michael Pfreundschuh. (2010) Rituximab in High-Grade Lymphoma. Seminars in Hematology 47:2, pages 148-155.
Crossref
Carsten Zwick, Josef Birkmann, Norma Peter, Heinrich Bodenstein, Roland Fuchs, Mathias Hänel, Marcel Reiser, Manfred Hensel, Michael Clemens, Samira Zeynalova, Marita Ziepert & Michael Pfreundschuh. (2008) Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Annals of Hematology 87:9, pages 717-726.
Crossref
Tara Seshadri, John Kuruvilla, Michael Crump & Armand Keating. (2008) Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation 14:3, pages 259-267.
Crossref
A Spencer, K Reed & C Arthur. (2007) Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Internal Medicine Journal 0:0, pages 070602000936001-???.
Crossref
Kirit M. Ardeshna, Nicholaos Kakouros, Wendi Qian, Michael G. Powell, Nishaat Saini, Shirley D'Sa, Stephen Mackinnon, Peter J. Hoskin, Anthony H. Goldstone & David C. Linch. (2005) Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. British Journal of Haematology 130:3, pages 363-372.
Crossref
Kesava Reddy, Stanton Goldman & Vinay K. Jain. (2004) Rasburicase for Prevention of Hyperuricemia and Tumor Lysis Syndrome. Supportive Cancer Therapy 1:2, pages 77-79.
Crossref
Bertrand CoiffierNicolas MounierSerge BolognaChristophe FerméHervé TillyAnne SonetBernard ChristianOlivier CasasnovasEric JourdanKarim BelhadjRaoul Herbrecht. (2003) Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study. Journal of Clinical Oncology 21:23, pages 4402-4406.
Crossref
Jia Bi, Byron M. Espina, Anil Tulpule, William Boswell & Alexandra M. Levine. (2001) High-Dose Cytosine–Arabinoside and Cisplatin Regimens as Salvage Therapy for Refractory or Relapsed AIDS-Related Non-Hodgkin's Lymphoma. JAIDS Journal of Acquired Immune Deficiency Syndromes 28:5, pages 416-421.
Crossref
Tarun KewalramaniAndrew D. ZelenetzEric E. HedrickGerard B. DonnellySonia HunteAnna C. PriovolosJing QinNancy Coady LyonsJoachim YahalomStephen D. NimerCraig H. Moskowitz. (2000) High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 96:7, pages 2399-2404.
Crossref
Ralph J. Hauke & James O. Armitage. (2000) Treatment of non-Hodgkin lymphoma. Current Opinion in Oncology 12:5, pages 412-418.
Crossref
. (1999) Hematotherapy LiteratureWatch. Journal of Hematotherapy & Stem Cell Research 8:5, pages 565-571.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.